Study of low-oxygen factors in hereditary bleeding disorder
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of HHT (usually from genetic testing or meeting at least 3 Curacao criteria).
- You are older than 17 years.
- You can understand the study and sign the consent form.
- You meet all the study “inclusion” needs—otherwise you can’t join.
- There are no extra eligibility details listed beyond having confirmed HHT and being able to consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks people with HHT (a genetic condition that causes abnormal blood vessels) to consider donating their body after death to help medical research. It aims to learn more about HHT by studying donated tissues.
This study looks at how hereditary hemorrhagic telangiectasia (HHT) affects your day-to-day life and well-being. By joining, you'll answer questions to help doctors better understand the impact of the condition.
This study evaluates the heart health of people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels. By participating, you help doctors understand how HHT affects the heart, which may improve future care.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
Hear when a new Hereditary Hemorrhagic Telangiectasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.